Results: In non-cirrhotic patients, sFLR showed a stronger correlation with serum total

bilirubin level than aFLR (R2 = 0.499 vs. 0.239). Posthepatectomy liver failure (PHLF) only developed in the group of sFLR 1.9 showed a 66.7% of sensitivity and 100% of specificity. Conclusion: Regardless of ICG R15 level, standardized FLR ≥ 25% in non-cirrhotic patients, and sFLR ≥ 25% with sFLR/ICG R15 > 1.9 in cirrhotic selleck compound patients was an acceptable limit of major hepatectomy. Key Word(s): 1. liver resection; 2. volumetry; 3. indocyanine test Presenting Author: SEOK HYUN KIM Additional Authors: HEON YOUNG LEE, BYUNG SEOK LEE, EAUM SEOK LEE, JONG SEOK JU Corresponding Author: SEOK HYUN KIM Affiliations: Chungnam National University, Chungnam National University, Chungnam National University Hospital, Chungnam National University Hospital Objective: Tenofovir was licensed in 2008 for the treatment of HBV infections in Europe and the United States and has been available in Korea since 2012. It has shown potent antiviral efficacy Talazoparib cost and safety against HBV infections. The aim of this study was to evaluate the biochemical response and virological response to tenofovir in real-life practice of HBV patients at six months after treatment with tenofovir. Methods: One hundred

and twenty-two chronic hepatitis B patients who took tenofovir for at least twelve months were enrolled. We investigated virological response (VR) and biochemical response (BR) by retrospectively reviewing medical records. We measured ALT levels, HBeAg, anti-HBe, HBV DNA, serum creatinine and phosphorous at six and twelve months after treatment with tenofovir. Results: The BR rate at six and twelve months after treatment selleck inhibitor with tenofovir in naïve patients were 75.0% and 85.4%, respectively. The VR rate at six and twelve months after treatment with tenofovir in naïve patients were 27.1% and 41.7%, respectively. High VR rate at six and twelve months after treatment were associated with initial low HBV DNA titer and initial negative HBeAg status. In this study nephrotoxicity due to tenofovir was not reported. Conclusion: Tenofovir induced good biochemical and virological

responses at six and twelve months after treatment in real-life practice of Korean patients with chronic hepatitis B. Key Word(s): 1. hepatitis B; 2. tenofovir; 3. efficacy; 4. safety Presenting Author: HAAK-CHEOUL KIM Additional Authors: EUN YOUNG CHO, SUCK CHEI CHOI Corresponding Author: HAAK-CHEOUL KIM Affiliations: Wonkwang Medical School and Hospital, Wonkwang Medical School and Hospital Objective: Hepatitis B virus (HBV) related hepatocellullar carcinoma (HCC) is one of the common malignant disorders. There is well known the different prevalence of the HCC development according to genotype, even to argue of it to subgenotype. Among them, HBV X protein (HBX) is most commonly implicated on carcinogenesis, as it affect the cellular and viral genes.